Novo Nordisk
Saxenda is now in low supply as Novo Nordisk issues a supply warning till 2023
Due to a shortage of Novo Nordisk’s popular obesity medicine Wegovy, there has been a surge in demand for their ...
GLP-1 medications from Novo Nordisk are being examined in Europe following reports suggest potential suicide risks
Following reports of two cases of suicidal thoughts and one case of self-harm among users in Iceland, the European Medicines ...
New lawsuits from Novo Nordisk are filed against synthetic versions of Wegovy and Ozempic
Source – FDA The increasing demand for GLP-1 drugs, which can lead to significant weight loss, has resulted in unauthorized ...
Novo Nordisk and Eli Lilly Drive Breakthroughs in Oral GLP-1 Treatments for Obesity at ADA Conference
Novo Nordisk and Eli Lilly showcased advancements in the development of oral GLP-1 treatments for Type II diabetes and obesity ...
Positive Phase IIIa Results: Once-Weekly Insulin Icodec Benefits Adults with Type 2 Diabetes
Source – Novo Nordisk Novo Nordisk, on June 25, 2023, released new findings from Phase IIIa trials, ONWARDS 1 and ...
EU Drug Regulator Scrutinizes Novo Nordisk and Eli Lilly Over GLP-1 Safety
The increased inspection of GLP-I therapies by the European Medicines Agency (EMA) has raised a warning about the possibility that ...
Novo Nordisk plans to stop compounded versions of Ozempic and Wegovy with fresh litigation
Source – Fierce Pharma Novo allegedly filed separate lawsuits against health spas, clinics, and pharmacies in Florida, New York, Tennessee, ...
Weight-Loss Medications Market Projected to Reach $60 Billion in 10 Years
According to a Morningstar analyst, frantic demand for pharmaceuticals to treat obesity from Novo Nordisk, Eli Lilly, and other companies ...
